Study evaluating the Safety and Efficacy of Etentamig (ABBV-383) in Subjects with Light Chain Amyloidosis

Status

Recruiting

Phases

Phase 1

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-503429-20-00

Acronym

M24-209

Enrollment

Registered

2024-05-06

Start date

2024-07-31

Completion date

Unknown

Last updated

2025-12-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Light Chain Amyloidosis

None listed

Sex/Gender

All

Age

18 Years to No maximum

France, Greece, Italy

None listed

Source: EU CTIS · Data processed: Feb 4, 2026